Kenneth L. Mueller, PhD

Kenneth L. Mueller, PhD
McNeill Baur PLLC
125 Cambridge Park Drive, Suite 301
Cambridge, MA 02140

Uniquely positioning clients to achieve their biotech and pharmaceutical IP strategy goals

Kenneth L. Mueller, PhD joins the firm with over 10-years of experience as a registered patent attorney litigating pharmaceutical patents for both generic and branded companies. Ken brings a deep understanding of trial tactics and procedure to his counseling practice that includes due diligence investigations, freedom-to-operate opinions, and pre-litigation strategy.

Ken has represented clients in a variety of complex technologies, including treatments for Parkinson’s Disease, multiple sclerosis, ADHD, hyponatremia, breast cancer, prostate cancer, and cleansing of the colon in preparation for colonoscopy, as well as devices for drug testing and software initiatives for business planning.

Ken has litigated in numerous district courts in declaratory judgment actions and Hatch-Waxman proceedings, as well as in front of the USPTO in IPR actions. His experience spans all stages of litigation, from developing an initial theory of the case to fact and expert discovery, summary judgement motions, and trial.

Ken has extensive biological and neuroscientific experience. This has allowed him to engage effectively in a variety of highly technical issues including, for example, the statistical interpretation of clinical trial results before an FDA Advisory board or, for another example, the amount of contamination at a particular stage of peptide synthesis in Markman proceedings.

Prior to joining McNeill Baur PLLC, Ken practiced in the IP litigation group at Womble Bond Dickinson (US) LLP and Goodwin Procter LLP.

Select Publications

Braintree v. Breckenridge and the potential danger of stipulation to a claim construction from an earlier case,” Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 14:40-44 (2017) (coauthor).

Website Incorporation into Contracts Requires Actual Notice Under the CISG,” Suffolk Transnational Law Review 37(2):489-501 (2014).

The receptors and coding logic for bitter taste,” Nature 434(7030): 225-9 (2005) (coauthor).

Coding of sweet, bitter, and umami tastes: different receptor cells sharing similar signaling pathways,” Cell 112(3):293-301 (2003) (coauthor).

A novel family of mammalian taste receptors,” Cell 100(6):693-702 (2000) (coauthor).

T2Rs function as bitter taste receptors,” Cell 100(6):703-11 (2000) (coauthor).

The vibrator mutation causes neurodegeneration via reduced expression of PITPa: positional complementation cloning and extragenic suppression,” Neuron 18(5):711-22 (1997) (coauthor).

Disruption of the nuclear hormone receptor RORa in staggerer mice,” Nature 379(6567):736-9 (1996) (coauthor).

A mutational study of the C-terminal zinc-finger motif of the Escherichia coli UvrA protein,” The Journal of Biological Chemistry 269(14):10771-5 (1994) (coauthor).





US Court of Appeals, Federal Circuit

US Patent and Trademark Office 



Suffolk University Law School,

JD, 2014


University of California, San Diego,

PhD, Biology, 2004


The Johns Hopkins University,

School of Hygiene and Public Health

Ms. Biochemistry


Haverford College,

BA, Biology, 1990